Genital Herpes (HSV-1 / HSV-2)
Prevalence, Stigma vs Reality, Suppressive Therapy, and the Disclosure Burden
Evidence grade 5 of 5, Settled. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Acyclovir, valacyclovir, famciclovir FDA-approved for HSV
Reference only. Not medical advice.
What can go wrong
For immunocompetent men, genital herpes is usually a recurrent nuisance rather than a dangerous infection, though first episodes can be severe. Important risks include neonatal herpes (rare but serious, mainly when a birthing person acquires HSV near delivery), more frequent or severe disease in immunocompromised people, and a modestly increased risk of HIV acquisition with HSV-2 infection. The largest harms for most men are psychological and relational: stigma, anxiety, and the disclosure burden. Antivirals reduce but do not eliminate transmission, and no current therapy cures latent infection.
This is something to take to a clinician. The Atlas can tell you what is known about genital herpes (hsv-1 / hsv-2) in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Genital herpes is caused by herpes simplex virus, either HSV-2 (traditionally the main cause of genital herpes) or HSV-1 (an increasing share of genital cases, largely via oral-genital contact). It is very common: a large fraction of adults carry HSV-1, and HSV-2 seroprevalence is substantial, though most infected people are unaware because the infection is often asymptomatic or unrecognized. The clinical reality is usually mild recurrent outbreaks, yet the social and psychological burden, driven by stigma, is frequently out of proportion to the medical impact. Antivirals (acyclovir, valacyclovir, famciclovir) shorten outbreaks and, used as daily suppressive therapy, reduce recurrences and lower transmission to partners. The CDC does not recommend routine type-specific serologic screening of asymptomatic people because of false-positive and counseling concerns.
Extremely common, medically minor for most, and burdened far more by stigma than by symptoms.
What people take it for
What it is taken for. Approval, where it exists, covers only some of these.
How it works
HSV infects epithelial cells, then travels along sensory nerves to establish lifelong latency in dorsal root or cranial ganglia, periodically reactivating to produce lesions or asymptomatic viral shedding. Nucleoside-analog antivirals (acyclovir and its prodrug valacyclovir, and famciclovir) are activated by viral thymidine kinase and inhibit viral DNA polymerase, suppressing replication during reactivation; they do not eradicate latent virus. Asymptomatic shedding, replication and release of virus without visible lesions, is the main reason transmission occurs even between outbreaks and even with condom use, since condoms reduce but do not eliminate skin-to-skin contact.
Stigma versus medical reality
Genital herpes is, for most people, a manageable recurrent skin condition, yet it carries disproportionate stigma that drives anxiety, relationship distress, and disclosure dread. Type-specific serologic testing is fraught: the CDC discourages routine HSV-2 antibody screening of asymptomatic, low-prevalence individuals because the positive predictive value is poor and a label can cause psychological harm without changing management. Suppressive valacyclovir reduces but does not eliminate transmission risk; partners benefit most from a combination of disclosure, suppressive therapy, and condoms. HSV-1 acquired orally in childhood can also be transmitted to the genitals of a partner through oral sex.
What people get wrong
Often saidIf you have no sores you cannot transmit herpes
ActuallyAsymptomatic viral shedding occurs between outbreaks, so transmission can happen without visible lesions; condoms and suppressive therapy reduce but do not eliminate the risk.
Often saidHerpes means a dangerous, life-altering disease
ActuallyFor most immunocompetent people genital herpes is a manageable recurrent skin condition; the stigma is usually far larger than the medical impact.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Causes
- HSV-2 and (increasingly) HSV-1
- Most carriers
- Unaware they are infected
- Latency site
- Sacral (genital) or trigeminal (oral) ganglia
- Antivirals
- Acyclovir, valacyclovir, famciclovir
- Suppression benefit
- Fewer recurrences and reduced transmission
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Genital Herpes (HSV-1 / HSV-2). A short entry is not a safe entry.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
- Where we land. We have not taken a position on this yet.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Corey et al., NEJM (valacyclovir for transmission)2004
Daily suppressive valacyclovir reduced HSV-2 transmission to susceptible partners
CDC STI Treatment Guidelines2021
Detailed episodic and suppressive regimens and discouraged routine type-specific serologic screening of asymptomatic persons
Tronstein et al., JAMA (asymptomatic shedding)2011
Demonstrated frequent genital HSV shedding even in people without symptoms